Make Informed Investment Decisions with Affordable Access to Experts
What Can We Expect from Celgene's Phase 3 REMARC Trial Data for Non-Hodgkin Lymphoma?Ticker(s): CELG
An oncologist with significant experience treating different types of lymphoma and a familiarity with the REMARC trial.
What is your background in treating lymphoma?Added By: kcmckee
What are your thoughts on the REMARC trial data presented to date?Added By: kcmckee
What factors do you think will potentially help or hurt revlimid make it to market for NHL?Added By: kcmckee
What attributes would make this application of revlimid superior (if at all) to existing drugs like rituximab or other recently approved options e.g. obinutuzumab, idelalisib and ibrutinib?Added By: kcmckee
Where do you see revlimid fitting into the NHL market?Added By: kcmckee
What do you currently prescribe for NHL and could you see yourself switching to revlimid or some other drug in the near future? What developments are you most excited for in the treatment of NHL?Added By: kcmckee
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
- Celgene and LYSARC Provide Update on the Phase III ‘REMARC' Study of REVLIMID Maintenance Treatment in Patients with Diffuse Large B-Cell Lymphoma Responding to First-Line R-CHOP Therapy CELG Occurred On: Jul 25, 2016
- Celgene's Phase 3 REMARC Data for non-Hodgkin Lymphoma Expected Mid-Year CELG Occurred On: Jul 25, 2016
- Phase 3 REMARC Trial Data with REVLIMID in DLBCL Maintenance Due Q4 2016 CELG Occurred On: Jul 25, 2016